Latest cardiac arrhythmia Stories
SAN CLEMENTE, Calif., April 26, 2012 /PRNewswire/ -- Cameron Health, Inc. ("Cameron Health"), a pioneer in the development, manufacture and distribution of next generation implantable cardioverter defibrillators (ICDs), announced today that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel voted 7-1 that sufficient data exists demonstrating the efficacy and safety of the S-ICD System for the treatment of sudden cardiac arrest (SCA). "We are pleased with the...
Successfully treating heart rhythm disorder improves long-term survival for cardiac surgery patients with atrial fibrillation A recent study conducted by Northwestern Medicine® researchers published in the Journal of Thoracic and Cardiovascular Surgery, reveals that patients with an abnormal heart rhythm known as atrial fibrillation (A-fib) who are undergoing cardiac surgery, have a lower long-term survival rate compared with patients who are in sinus rhythm, which is the normal beating...
Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar. Patients with certain types of atrial fibrillation, or irregular heartbeat, take these drugs to reduce the risks of clots that could lead to a stroke. Sometimes they are instructed to stop taking the medication temporarily before surgery or...
Successfully treating heart rhythm disorder improves long-term survival for cardiac surgery patients with atrial fibrillation CHICAGO, April 25, 2012 /PRNewswire-USNewswire/ -- A recent study conducted by Northwestern Medicine® researchers published in the Journal of Thoracic and Cardiovascular Surgery, reveals that patients with an abnormal heart rhythm known as atrial fibrillation (A-fib) who are undergoing cardiac surgery, have a lower long-term survival rate compared with...
CLEVELAND, April 16, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Jim Bullock as Chairman of the Company's Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO ) Mr. Bullock is a leader in the cardiac rhythm management field and has served as Chief Executive Officer of Atritech, an electrophysiology company that was...
NATICK, Mass., April 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the U.S. market launch of its Z Flex-270(TM) Steerable Sheath. The device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart. The Company plans to launch the product immediately in the U.S. "The Z Flex-270 Steerable Sheath provides more than 270 degrees of tip...
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA. Myotonic dystrophy type 1 (DM 1) is the...
MORRISVILLE, N.C., March 27, 2012 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, today announced that CEO John Funkhouser spoke at the American College of Cardiology's (ACC) Cardiovascular Innovations Educational Forum in Chicago, IL, on the future of cardiac ablation under managed care. The theme of the talk was anticipated managed care requirements for the industry, and though the exact form they will take is uncertain, the presentation...
New drugs available to prevent strokes and control heart rhythm The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines. Atrial fibrillation is the most common cardiac arrhythmia and is a significant cause of stroke, illness in general, and death. It is, for example, the leading cause of stroke in the elderly. The past year has seen important changes in the drugs available to treat atrial fibrillation and...
CAMBRIDGE, England, March 20, 2012 /PRNewswire/ -- XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally. The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and...
